case_images: PMC10896944_01
case_images: (A-C). T cell-specific and unspecific response evaluated by the detection of IFN-gamma in PBMC and BMMC and evaluation of the timeline of virological replication during anti-SARS-CoV-2 treatments in a COVID-19 patient receiving an allogenic hematopoietic stem cell transplantation. Black line in (C) indicates the m-NPS negativity. IFN-gamma, Interferon-gamma; SEB: staphylococcal enterotoxin B; Spike: SARS-CoV-2 CD4 pool of peptides; DELTA: B.1.617.2 SARS-CoV-2 variant, OMICRON: B.1.1.529 SARS-CoV-2 variant; EBV: Epstein-Barr virus; CMV: cytomegalovirus.
case_images: fonc-14-1290614-g001.jpg
case_images: PMC10896944_01_fonc-14-1290614-g001.jpg
case_images: f1
case_images: At day 7 in PBMCs, after a long-term in vitro stimulation (red bar), we found a rescued SARS-CoV-2-specific response against spike from the ancestral strain and from delta and omicron variants ( Figure 1A ); also EBV-specific response was recovered. Differently, in BMMCs at day 7 we found only a weak and selective positive response to the spike from the omicron variant ( Figure 1B ). Voriconazole was replaced by isovuconazole (200 mg daily) to avoid drug-drug interaction with ritonavir ( Figure 1C ), and cyclosporine plasma level was monitored every 48 hours.